MX2018004381A - Combinacion que comprende un compuesto de aminotiolester o una de sus sales farmaceuticamente aceptables y un compuesto capaz de aumentar el nivel de peroxido de hidrogeno (h2o2) en las celulas cancerosas de un sujeto. - Google Patents

Combinacion que comprende un compuesto de aminotiolester o una de sus sales farmaceuticamente aceptables y un compuesto capaz de aumentar el nivel de peroxido de hidrogeno (h2o2) en las celulas cancerosas de un sujeto.

Info

Publication number
MX2018004381A
MX2018004381A MX2018004381A MX2018004381A MX2018004381A MX 2018004381 A MX2018004381 A MX 2018004381A MX 2018004381 A MX2018004381 A MX 2018004381A MX 2018004381 A MX2018004381 A MX 2018004381A MX 2018004381 A MX2018004381 A MX 2018004381A
Authority
MX
Mexico
Prior art keywords
compound
subject
pharmaceutically acceptable
level
acceptable salt
Prior art date
Application number
MX2018004381A
Other languages
English (en)
Inventor
Martin Guillaume
Ceylan Ismail
QUASH Gerry
Perez-Alea Mileidys
Original Assignee
Advanced Biodesign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biodesign filed Critical Advanced Biodesign
Publication of MX2018004381A publication Critical patent/MX2018004381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una combinación que comprende un compuesto de aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto capaz de aumentar el nivel de H2O2 en las células cancerosas de un sujeto, para usarse como un medicamento. La presente invención se refiere a una combinación que comprende un compuesto de aminotioléster o una sal farmacéuticamente aceptable del mismo, en particular el 4-(dimetilamino)-4-metilpent-2-inotioato de S-metilo o una sal farmacéuticamente aceptable del mismo, y más particularmente el fumarato del éster S-metílico del ácido 4-(dimetilamino)-4-metil-2-pentinotioico, y un compuesto capaz de aumentar el nivel de H2O2 en las células cancerosas de un sujeto, en particular para usarse en el tratamiento del cáncer en un sujeto, en donde las células cancerosas del sujeto no producen en exceso H2O2 en comparación con un valor de control y tiene un nivel de GSH por debajo de 5 nmol para 25000 células.
MX2018004381A 2015-10-15 2016-10-14 Combinacion que comprende un compuesto de aminotiolester o una de sus sales farmaceuticamente aceptables y un compuesto capaz de aumentar el nivel de peroxido de hidrogeno (h2o2) en las celulas cancerosas de un sujeto. MX2018004381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306650 2015-10-15
PCT/EP2016/074682 WO2017064241A1 (en) 2015-10-15 2016-10-14 Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject

Publications (1)

Publication Number Publication Date
MX2018004381A true MX2018004381A (es) 2018-05-11

Family

ID=54360386

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004381A MX2018004381A (es) 2015-10-15 2016-10-14 Combinacion que comprende un compuesto de aminotiolester o una de sus sales farmaceuticamente aceptables y un compuesto capaz de aumentar el nivel de peroxido de hidrogeno (h2o2) en las celulas cancerosas de un sujeto.

Country Status (21)

Country Link
US (1) US10406125B2 (es)
EP (1) EP3362094B1 (es)
JP (1) JP7062592B2 (es)
CN (1) CN108348612A (es)
AR (1) AR106351A1 (es)
CA (1) CA3001201C (es)
CY (1) CY1123916T1 (es)
DK (1) DK3362094T3 (es)
ES (1) ES2870508T3 (es)
HK (1) HK1251477A1 (es)
HR (1) HRP20210358T1 (es)
HU (1) HUE054247T2 (es)
IL (1) IL258658B (es)
LT (1) LT3362094T (es)
MX (1) MX2018004381A (es)
PL (1) PL3362094T3 (es)
PT (1) PT3362094T (es)
RS (1) RS61572B1 (es)
SI (1) SI3362094T1 (es)
WO (1) WO2017064241A1 (es)
ZA (1) ZA201802400B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220039722A (ko) * 2019-07-31 2022-03-29 어드방스드 비오디자인 아미노티올에스터 화합물 및 이의 용도
FR3119314A1 (fr) * 2021-01-29 2022-08-05 Advanced Biodesign Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable
EP4035666A1 (en) * 2021-01-29 2022-08-03 Advanced Biodesign Aminothiolester compound or derivative thereof for use as an immunomodulatory agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
FR2809727B1 (fr) 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations

Also Published As

Publication number Publication date
CA3001201C (en) 2023-07-11
ZA201802400B (en) 2020-01-29
CN108348612A (zh) 2018-07-31
EP3362094B1 (en) 2021-02-17
DK3362094T3 (da) 2021-03-01
US20180303773A1 (en) 2018-10-25
US10406125B2 (en) 2019-09-10
SI3362094T1 (sl) 2021-04-30
CY1123916T1 (el) 2022-05-27
LT3362094T (lt) 2021-05-10
EP3362094A1 (en) 2018-08-22
JP7062592B2 (ja) 2022-05-06
HK1251477A1 (zh) 2019-02-01
IL258658A (en) 2018-06-28
WO2017064241A1 (en) 2017-04-20
JP2018531995A (ja) 2018-11-01
HRP20210358T1 (hr) 2021-04-16
IL258658B (en) 2021-04-29
HUE054247T2 (hu) 2021-08-30
PL3362094T3 (pl) 2021-10-11
BR112018007480A2 (pt) 2018-10-23
RS61572B1 (sr) 2021-04-29
AR106351A1 (es) 2018-01-03
PT3362094T (pt) 2021-04-15
ES2870508T3 (es) 2021-10-27
CA3001201A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MY196330A (en) Diacylglycerol Acyltransferase 2 Inhibitors
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
NZ773453A (en) 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
MX2020013059A (es) Inhibidores de calicreina plasmatica humana.
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer&#39;s disease
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
PH12016501654A1 (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
CY1123916T1 (el) Συνδυασmος που περιλαμβανει mιa ενωση αμινοθειολεστερα ή ενα φαρμακευτικως αποδεκτο αλας αυτης και mιa ενωση ικανη αυξησης του επιπεδου η2ο2 στα καρκινικα κυτταρα ενος υποκειμενου
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2017014912A (es) Compuesto para la profilaxis o el tratamiento de daño al organo.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2018004380A (es) Compuestos de aminotiolesteres o sus sales farmaceuticamente aceptables para usarse en el tratamiento del cancer.
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer&#39;s disease
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
PH12016502527A1 (en) Stabilized desmopressin
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
MX2017011093A (es) Terapia combinada de roneparstat para mieloma multiple.

Legal Events

Date Code Title Description
FG Grant or registration